AZD1163 / AstraZeneca - LARVOL DELTA

A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=99 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Apr 2026 ➔ Oct 2025 | Trial primary completion date: Apr 2025 ➔ Oct 2025

Trial completion date • Trial primary completion date

Blockade of Soluble and Cell Surface PAD Activity Prevents the Generation of Citrullinated Autoantigens Recognized by RA Patients' Serum (ACR Convergence 2024) - P1 | "AZD1163 is a bi-specific anti-PAD2/4 antibody in phase I clinical trials (NCT06103877) for the treatment of RA. AZD1163 blocks the enzymic activity of soluble and membrane PAD2 and PAD4 preventing protein citrullination. Targeting the generation of the citrullinated autoantigens that drive autoimmunity and chronic inflammatory responses in the joints is a novel approach for the treatment of RA."

Clinical • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=99 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Apr 2025 ➔ Apr 2026

Trial completion date

AZD1163 - FIRST-IN-CLASS ANTI-PAD2/4 BI-SPECIFIC ANTIBODY TO INHIBIT AUTOANTIGEN FORMATION IN RHEUMATOID ARTHRITIS (EULAR 2024) - "We describe generation of a novel potent bi-specific anti-PAD2/4 antibody (AZD1163) that inhibits neutrophil PADs, the enzymes responsible for the generation of citrullinated autoantigens in RA. Moreover, we found no evidence for neutrophil activation by this bi-specific antibody. In non-human primates, AZD1163 exhibited favourable PK/PD properties that merit progression to clinical trials."

Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=99 | Recruiting | Sponsor: AstraZeneca | N=28 ➔ 99

Enrollment change

A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=28 | Recruiting | Sponsor: AstraZeneca | N=64 ➔ 28

Enrollment change